NEW YORK, March 4, 2019 /PRNewswire/ -- Phosphorus Inc., a leader in diagnostic and bioinformatic solutions for clinical Next Generation Sequencing (NGS), announced today that the company's laboratory received approval to market the PhosphorusONE test from the New York State Department of Health. PhosphorusONE is the third test approved for Phosphorus in the state in the past three months. In late 2018, Phosphorus received approval for its Heart Disease test for Arrhythmias, Cardiomyopathies and Lipidemias, and approval for its Hereditary Cancer germ line test.
The PhosphorusONE test is the most comprehensive assessment of genetic health meant for identifying and preventing risk for genetic conditions. The healthy screen analyzes 375 genes covering 170 inherited conditions and 175 different drug reactions. It provides information on a person's genetic health risk for certain disease (such as cancer, heart disease, dementia, and vision loss), it assesses predisposition to adverse reaction to drugs and therapeutics, and assesses certain wellness traits.
"We are very excited to have received approval from New York State for PhosphorusONE," said Alex Bisignano, Phosphorus' CEO. "This is the only test of its kind that has earned NYSDOH approval and as such we feel honored to enable New York state residents to gain access to it. PhosphorusONE will provide valuable information about an individual's health profile at an affordable price. We take great pride in delivering excellent quality in everything we do at Phosphorus from our lab results to our software to our customer support. The New York State Department of Health demands that companies meet a high standard of quality in testing and rigor in process, and we are pleased to earn their approval to offer this comprehensive, valuable test."
"Historically, genetic tests to screen for disease have been limited to high-risk populations - individuals who either already are symptomatic or affected with a particular condition. By bringing down the cost of a holistic screen, the PhosphorusONE test provides the opportunity to maximize disease prevention and early detection amongst not just the high-risk, but the general population. Therefore, the NYS approval speaks not only to the quality of our testing, but allows us to reach our NYS residents that may not otherwise qualify for routine genetic testing based on their family history," stated Malgorzata Jaremko, SVP and laboratory director of Phosphorus.
Phosphorus's mission is to improve human health by better understanding and harnessing the power of the human genome. Having built the most comprehensive, high-quality, and cost-effective portfolio of genetic tests, Phosphorus is able to increase access and quality of care in the burgeoning field of genomics. The company currently provides panel-based, constitutional genetic testing in the specialty areas of Fertility, Cardiology, Lipidology, Oncology, Pharmacogenetics, Ophthalmology, Neurology, and Pediatric/Metabolic disorders. Phosphorus also offers the PhosphorusONE proactive health screen - the most comprehensive genomic test for taking a proactive look at your health. Additionally, Phosphorus provides the ElementsTM software platform to enable any laboratory to easily deploy any of the Phosphorus genetic tests on-premise as a local solution. For more information, please visit our website at phosphorus.com.